Morepen Laboratories Limited (MOREPENLAB.BO) Stock Competitors & Peer Comparison

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, SUNPHARMA.BO has a market cap of 4.3T. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while SUNPHARMA.BO trades at ₹1,788.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas SUNPHARMA.BO's P/E ratio is 39.20. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to SUNPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check SUNPHARMA.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, SUNPHARMA.NS has a market cap of 4.3T. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while SUNPHARMA.NS trades at ₹1,788.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas SUNPHARMA.NS's P/E ratio is 37.22. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to SUNPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check SUNPHARMA.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, DIVISLAB.BO has a market cap of 1.8T. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while DIVISLAB.BO trades at ₹6,516.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas DIVISLAB.BO's P/E ratio is 68.55. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to DIVISLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check DIVISLAB.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, DIVISLAB.NS has a market cap of 1.8T. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while DIVISLAB.NS trades at ₹6,521.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas DIVISLAB.NS's P/E ratio is 68.50. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to DIVISLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check DIVISLAB.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, TORNTPHARM.NS has a market cap of 1.5T. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while TORNTPHARM.NS trades at ₹4,410.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas TORNTPHARM.NS's P/E ratio is 69.29. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to TORNTPHARM.NS's ROE of +0.27%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to TORNTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check TORNTPHARM.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, TORNTPHARM.BO has a market cap of 1.5T. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while TORNTPHARM.BO trades at ₹4,412.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas TORNTPHARM.BO's P/E ratio is 69.86. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to TORNTPHARM.BO's ROE of +0.27%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to TORNTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check TORNTPHARM.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, ZYDUSLIFE.NS has a market cap of 1.1T. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while ZYDUSLIFE.NS trades at ₹1,087.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas ZYDUSLIFE.NS's P/E ratio is 21.75. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to ZYDUSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check ZYDUSLIFE.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, ZYDUSLIFE.BO has a market cap of 1.1T. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while ZYDUSLIFE.BO trades at ₹1,087.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas ZYDUSLIFE.BO's P/E ratio is 21.76. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to ZYDUSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check ZYDUSLIFE.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, DRREDDY.NS has a market cap of 1.1T. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while DRREDDY.NS trades at ₹1,275.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas DRREDDY.NS's P/E ratio is 24.84. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to DRREDDY.NS's ROE of +0.12%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to DRREDDY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check DRREDDY.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, DRREDDY.BO has a market cap of 1.1T. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while DRREDDY.BO trades at ₹1,275.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas DRREDDY.BO's P/E ratio is 18.84. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to DRREDDY.BO's ROE of +0.12%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to DRREDDY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check DRREDDY.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, LUPIN.NS has a market cap of 1T. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while LUPIN.NS trades at ₹2,254.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas LUPIN.NS's P/E ratio is 19.46. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to LUPIN.NS's ROE of +0.28%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to LUPIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check LUPIN.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, LUPIN.BO has a market cap of 1T. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while LUPIN.BO trades at ₹2,252.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas LUPIN.BO's P/E ratio is 24.03. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to LUPIN.BO's ROE of +0.28%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to LUPIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check LUPIN.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, MANKIND.BO has a market cap of 964.9B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while MANKIND.BO trades at ₹2,350.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas MANKIND.BO's P/E ratio is 50.54. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to MANKIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check MANKIND.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, MANKIND.NS has a market cap of 964.6B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while MANKIND.NS trades at ₹2,357.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas MANKIND.NS's P/E ratio is 50.40. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to MANKIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check MANKIND.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, AUROPHARMA.BO has a market cap of 849.5B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while AUROPHARMA.BO trades at ₹1,451.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas AUROPHARMA.BO's P/E ratio is 24.84. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to AUROPHARMA.BO's ROE of +0.10%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to AUROPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check AUROPHARMA.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, AUROPHARMA.NS has a market cap of 841.4B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while AUROPHARMA.NS trades at ₹1,451.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas AUROPHARMA.NS's P/E ratio is 24.25. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to AUROPHARMA.NS's ROE of +0.10%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to AUROPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check AUROPHARMA.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, LAURUSLABS.BO has a market cap of 781.2B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while LAURUSLABS.BO trades at ₹1,404.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas LAURUSLABS.BO's P/E ratio is 90.55. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to LAURUSLABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check LAURUSLABS.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, LAURUSLABS.NS has a market cap of 781.1B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while LAURUSLABS.NS trades at ₹1,404.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas LAURUSLABS.NS's P/E ratio is 92.62. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to LAURUSLABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check LAURUSLABS.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, ALKEM.NS has a market cap of 627.9B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while ALKEM.NS trades at ₹5,356.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas ALKEM.NS's P/E ratio is 27.27. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to ALKEM.NS's ROE of +0.18%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to ALKEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check ALKEM.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, ALKEM.BO has a market cap of 627.9B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while ALKEM.BO trades at ₹5,351.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas ALKEM.BO's P/E ratio is 27.27. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to ALKEM.BO's ROE of +0.18%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to ALKEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check ALKEM.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, GLENMARK.NS has a market cap of 611.3B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while GLENMARK.NS trades at ₹2,176.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas GLENMARK.NS's P/E ratio is 44.95. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to GLENMARK.NS's ROE of +0.14%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to GLENMARK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check GLENMARK.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, GLENMARK.BO has a market cap of 611.1B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while GLENMARK.BO trades at ₹2,178.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas GLENMARK.BO's P/E ratio is 44.92. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to GLENMARK.BO's ROE of +0.14%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to GLENMARK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check GLENMARK.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, IPCALAB.BO has a market cap of 416.8B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while IPCALAB.BO trades at ₹1,647.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas IPCALAB.BO's P/E ratio is 36.58. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to IPCALAB.BO's ROE of +0.15%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to IPCALAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check IPCALAB.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, IPCALAB.NS has a market cap of 416.6B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while IPCALAB.NS trades at ₹1,649.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas IPCALAB.NS's P/E ratio is 36.54. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to IPCALAB.NS's ROE of +0.15%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to IPCALAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check IPCALAB.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while SUVENPHAR.NS trades at ₹1,078.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to SUVENPHAR.NS's ROE of +0.09%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to SUVENPHAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check SUVENPHAR.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while SUVENPHAR.BO trades at ₹1,075.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to SUVENPHAR.BO's ROE of +0.07%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to SUVENPHAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check SUVENPHAR.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, AJANTPHARM.BO has a market cap of 372B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while AJANTPHARM.BO trades at ₹2,970.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas AJANTPHARM.BO's P/E ratio is 36.71. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to AJANTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check AJANTPHARM.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, AJANTPHARM.NS has a market cap of 371.9B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while AJANTPHARM.NS trades at ₹2,968.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas AJANTPHARM.NS's P/E ratio is 35.18. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to AJANTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check AJANTPHARM.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, JBCHEPHARM.BO has a market cap of 348.3B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while JBCHEPHARM.BO trades at ₹2,178.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas JBCHEPHARM.BO's P/E ratio is 48.75. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to JBCHEPHARM.BO's ROE of +0.19%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to JBCHEPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check JBCHEPHARM.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, JBCHEPHARM.NS has a market cap of 348.3B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while JBCHEPHARM.NS trades at ₹2,172.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas JBCHEPHARM.NS's P/E ratio is 48.74. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to JBCHEPHARM.NS's ROE of +0.19%. Regarding short-term risk, MOREPENLAB.BO and JBCHEPHARM.NS have similar daily volatility (4.35).Check JBCHEPHARM.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, EMCURE.NS has a market cap of 333.1B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while EMCURE.NS trades at ₹1,719.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas EMCURE.NS's P/E ratio is 36.08. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to EMCURE.NS's ROE of +0.20%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to EMCURE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check EMCURE.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, WOCKPHARMA.NS has a market cap of 312.1B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while WOCKPHARMA.NS trades at ₹1,892.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas WOCKPHARMA.NS's P/E ratio is 145.85. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to WOCKPHARMA.NS's ROE of +0.05%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to WOCKPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check WOCKPHARMA.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, WOCKPHARMA.BO has a market cap of 312B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while WOCKPHARMA.BO trades at ₹1,893.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas WOCKPHARMA.BO's P/E ratio is 145.58. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to WOCKPHARMA.BO's ROE of +0.05%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to WOCKPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check WOCKPHARMA.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while PEL.NS trades at ₹1,124.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to PEL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check PEL.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, PPLPHARMA.NS has a market cap of 220.9B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while PPLPHARMA.NS trades at ₹165.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas PPLPHARMA.NS's P/E ratio is -68.07. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to PPLPHARMA.NS's ROE of -0.04%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to PPLPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check PPLPHARMA.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, PPLPHARMA.BO has a market cap of 220.9B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while PPLPHARMA.BO trades at ₹165.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas PPLPHARMA.BO's P/E ratio is -68.06. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to PPLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check PPLPHARMA.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, NEULANDLAB.BO has a market cap of 215.7B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while NEULANDLAB.BO trades at ₹16,959.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas NEULANDLAB.BO's P/E ratio is 59.33. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to NEULANDLAB.BO's ROE of +0.22%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to NEULANDLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check NEULANDLAB.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, NEULANDLAB.NS has a market cap of 215.7B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while NEULANDLAB.NS trades at ₹16,964.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas NEULANDLAB.NS's P/E ratio is 59.35. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to NEULANDLAB.NS's ROE of +0.22%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to NEULANDLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check NEULANDLAB.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, ASTRAZEN.NS has a market cap of 215B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while ASTRAZEN.NS trades at ₹8,343.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas ASTRAZEN.NS's P/E ratio is 114.21. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to ASTRAZEN.NS's ROE of +0.23%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to ASTRAZEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check ASTRAZEN.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, ASTRAZEN.BO has a market cap of 215B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while ASTRAZEN.BO trades at ₹8,383.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas ASTRAZEN.BO's P/E ratio is 114.30. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to ASTRAZEN.BO's ROE of +0.23%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to ASTRAZEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check ASTRAZEN.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, GRANULES.NS has a market cap of 195.7B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while GRANULES.NS trades at ₹766.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas GRANULES.NS's P/E ratio is 32.30. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to GRANULES.NS's ROE of +0.14%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to GRANULES.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check GRANULES.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, GRANULES.BO has a market cap of 191.6B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while GRANULES.BO trades at ₹767.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas GRANULES.BO's P/E ratio is 35.11. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to GRANULES.BO's ROE of +0.14%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to GRANULES.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check GRANULES.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, ERIS.NS has a market cap of 189.2B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while ERIS.NS trades at ₹1,365.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas ERIS.NS's P/E ratio is 30.16. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to ERIS.NS's ROE of +0.19%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to ERIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check ERIS.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, ERIS.BO has a market cap of 188.6B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while ERIS.BO trades at ₹1,365.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas ERIS.BO's P/E ratio is 30.07. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to ERIS.BO's ROE of +0.19%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to ERIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check ERIS.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, COHANCE.NS has a market cap of 164.9B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while COHANCE.NS trades at ₹424.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas COHANCE.NS's P/E ratio is 92.31. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to COHANCE.NS's ROE of +0.06%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to COHANCE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check COHANCE.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, COHANCE.BO has a market cap of 164.9B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while COHANCE.BO trades at ₹424.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas COHANCE.BO's P/E ratio is 92.28. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to COHANCE.BO's ROE of +0.06%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to COHANCE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check COHANCE.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, NATCOPHARM.BO has a market cap of 160.1B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while NATCOPHARM.BO trades at ₹868.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas NATCOPHARM.BO's P/E ratio is 10.40. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to NATCOPHARM.BO's ROE of +0.17%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to NATCOPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check NATCOPHARM.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, NATCOPHARM.NS has a market cap of 160B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while NATCOPHARM.NS trades at ₹868.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas NATCOPHARM.NS's P/E ratio is 11.28. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to NATCOPHARM.NS's ROE of +0.17%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to NATCOPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check NATCOPHARM.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, CAPLIPOINT.NS has a market cap of 154.5B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while CAPLIPOINT.NS trades at ₹2,111.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas CAPLIPOINT.NS's P/E ratio is 24.20. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to CAPLIPOINT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check CAPLIPOINT.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, CAPLIPOINT.BO has a market cap of 154.4B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while CAPLIPOINT.BO trades at ₹2,110.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas CAPLIPOINT.BO's P/E ratio is 24.18. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to CAPLIPOINT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check CAPLIPOINT.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, JUBLPHARMA.NS has a market cap of 154.2B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while JUBLPHARMA.NS trades at ₹957.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas JUBLPHARMA.NS's P/E ratio is 38.88. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to JUBLPHARMA.NS's ROE of +0.06%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to JUBLPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check JUBLPHARMA.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, JUBLPHARMA.BO has a market cap of 154.2B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while JUBLPHARMA.BO trades at ₹948.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas JUBLPHARMA.BO's P/E ratio is 38.83. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to JUBLPHARMA.BO's ROE of +0.06%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to JUBLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check JUBLPHARMA.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, APLLTD.NS has a market cap of 145.1B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while APLLTD.NS trades at ₹745.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas APLLTD.NS's P/E ratio is 21.53. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to APLLTD.NS's ROE of +0.13%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to APLLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check APLLTD.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, APLLTD.BO has a market cap of 144.9B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while APLLTD.BO trades at ₹745.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas APLLTD.BO's P/E ratio is 21.45. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to APLLTD.BO's ROE of +0.13%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to APLLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check APLLTD.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while GLS.NS trades at ₹1,086.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to GLS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check GLS.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while GLS.BO trades at ₹1,085.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to GLS.BO's ROE of +0.09%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to GLS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check GLS.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, ALIVUS.NS has a market cap of 126.7B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while ALIVUS.NS trades at ₹1,002.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas ALIVUS.NS's P/E ratio is 22.50. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to ALIVUS.NS's ROE of +0.18%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to ALIVUS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check ALIVUS.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, ALIVUS.BO has a market cap of 126.5B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while ALIVUS.BO trades at ₹1,000.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas ALIVUS.BO's P/E ratio is 22.47. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to ALIVUS.BO's ROE of +0.21%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to ALIVUS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check ALIVUS.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, VIYASH.NS has a market cap of 111.4B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while VIYASH.NS trades at ₹251.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas VIYASH.NS's P/E ratio is 63.50. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to VIYASH.NS's ROE of +0.09%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to VIYASH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check VIYASH.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while CAPPL.BO trades at ₹1,446.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to CAPPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check CAPPL.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, SHILPAMED.NS has a market cap of 105.2B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while SHILPAMED.NS trades at ₹532.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas SHILPAMED.NS's P/E ratio is 43.18. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to SHILPAMED.NS's ROE of +0.10%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to SHILPAMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check SHILPAMED.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, PGHL.NS has a market cap of 102.9B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while PGHL.NS trades at ₹6,199.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas PGHL.NS's P/E ratio is 31.44. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to PGHL.NS's ROE of +0.59%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to PGHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check PGHL.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, PGHL.BO has a market cap of 102.5B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while PGHL.BO trades at ₹6,201.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas PGHL.BO's P/E ratio is 31.36. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to PGHL.BO's ROE of +0.59%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to PGHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check PGHL.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, STAR.NS has a market cap of 96.3B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while STAR.NS trades at ₹1,005.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas STAR.NS's P/E ratio is 17.32. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to STAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check STAR.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, STAR.BO has a market cap of 96.1B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while STAR.BO trades at ₹1,005.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas STAR.BO's P/E ratio is 17.29. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to STAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check STAR.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, SUDEEPPHRM.NS has a market cap of 85.2B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while SUDEEPPHRM.NS trades at ₹729.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas SUDEEPPHRM.NS's P/E ratio is 50.60. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to SUDEEPPHRM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check SUDEEPPHRM.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, AKUMS.NS has a market cap of 84.8B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while AKUMS.NS trades at ₹545.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas AKUMS.NS's P/E ratio is 33.20. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to AKUMS.NS's ROE of +0.08%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to AKUMS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check AKUMS.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, SPARC.NS has a market cap of 69.1B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while SPARC.NS trades at ₹203.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas SPARC.NS's P/E ratio is 4.45. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to SPARC.NS's ROE of +11.09%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to SPARC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check SPARC.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, SPARC.BO has a market cap of 68.9B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while SPARC.BO trades at ₹203.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas SPARC.BO's P/E ratio is 4.44. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to SPARC.BO's ROE of +11.09%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to SPARC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check SPARC.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, FDC.NS has a market cap of 62B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while FDC.NS trades at ₹381.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas FDC.NS's P/E ratio is 22.05. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to FDC.NS's ROE of +0.12%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to FDC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check FDC.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, FDC.BO has a market cap of 62B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while FDC.BO trades at ₹381.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas FDC.BO's P/E ratio is 22.02. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to FDC.BO's ROE of +0.12%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to FDC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check FDC.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, AARTIPHARM.BO has a market cap of 57.1B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while AARTIPHARM.BO trades at ₹606.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas AARTIPHARM.BO's P/E ratio is 32.66. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to AARTIPHARM.BO's ROE of +0.09%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to AARTIPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check AARTIPHARM.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, AARTIPHARM.NS has a market cap of 57B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while AARTIPHARM.NS trades at ₹606.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas AARTIPHARM.NS's P/E ratio is 32.64. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to AARTIPHARM.NS's ROE of +0.09%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to AARTIPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check AARTIPHARM.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, SUVEN.BO has a market cap of 55B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while SUVEN.BO trades at ₹233.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas SUVEN.BO's P/E ratio is -19.26. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to SUVEN.BO's ROE of -1.01%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to SUVEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check SUVEN.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, SUVEN.NS has a market cap of 53.2B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while SUVEN.NS trades at ₹233.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas SUVEN.NS's P/E ratio is -19.55. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to SUVEN.NS's ROE of -1.01%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to SUVEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check SUVEN.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, SHILPAMED.BO has a market cap of 52.5B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while SHILPAMED.BO trades at ₹532.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas SHILPAMED.BO's P/E ratio is 43.22. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to SHILPAMED.BO's ROE of +0.10%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to SHILPAMED.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check SHILPAMED.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while SEQUENT.BO trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to SEQUENT.BO's ROE of +0.06%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to SEQUENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check SEQUENT.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while SEQUENT.NS trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to SEQUENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check SEQUENT.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, INNOVACAP.NS has a market cap of 49.6B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while INNOVACAP.NS trades at ₹870.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas INNOVACAP.NS's P/E ratio is 35.26. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to INNOVACAP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check INNOVACAP.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, BLISSGVS.NS has a market cap of 46.4B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while BLISSGVS.NS trades at ₹419.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas BLISSGVS.NS's P/E ratio is 36.53. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to BLISSGVS.NS's ROE of +0.12%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to BLISSGVS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check BLISSGVS.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, BLISSGVS.BO has a market cap of 46.3B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while BLISSGVS.BO trades at ₹419.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas BLISSGVS.BO's P/E ratio is 36.50. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to BLISSGVS.BO's ROE of +0.12%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to BLISSGVS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check BLISSGVS.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, GUJTHEM.NS has a market cap of 45B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while GUJTHEM.NS trades at ₹401.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas GUJTHEM.NS's P/E ratio is 96.09. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to GUJTHEM.NS's ROE of +0.17%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to GUJTHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check GUJTHEM.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, ORCHPHARMA.NS has a market cap of 42.8B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while ORCHPHARMA.NS trades at ₹842.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas ORCHPHARMA.NS's P/E ratio is 208.97. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to ORCHPHARMA.NS's ROE of +0.02%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to ORCHPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check ORCHPHARMA.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, ORCHPHARMA.BO has a market cap of 42.7B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while ORCHPHARMA.BO trades at ₹845.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas ORCHPHARMA.BO's P/E ratio is 205.72. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to ORCHPHARMA.BO's ROE of +0.02%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to ORCHPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check ORCHPHARMA.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, IOLCP.NS has a market cap of 38.7B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while IOLCP.NS trades at ₹126.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas IOLCP.NS's P/E ratio is 28.14. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to IOLCP.NS's ROE of +0.08%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to IOLCP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check IOLCP.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, IOLCP.BO has a market cap of 38.6B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while IOLCP.BO trades at ₹126.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas IOLCP.BO's P/E ratio is 28.05. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to IOLCP.BO's ROE of +0.08%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to IOLCP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check IOLCP.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, GUFICBIO.NS has a market cap of 37.1B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while GUFICBIO.NS trades at ₹376.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas GUFICBIO.NS's P/E ratio is 57.71. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to GUFICBIO.NS's ROE of +0.10%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to GUFICBIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check GUFICBIO.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, GUFICBIO.BO has a market cap of 37.1B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while GUFICBIO.BO trades at ₹376.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas GUFICBIO.BO's P/E ratio is 57.83. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to GUFICBIO.BO's ROE of +0.10%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to GUFICBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check GUFICBIO.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, RPGLIFE.BO has a market cap of 35.8B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while RPGLIFE.BO trades at ₹2,086.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas RPGLIFE.BO's P/E ratio is 31.06. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to RPGLIFE.BO's ROE of +0.21%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to RPGLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check RPGLIFE.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, RPGLIFE.NS has a market cap of 35.8B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while RPGLIFE.NS trades at ₹2,089.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas RPGLIFE.NS's P/E ratio is 31.00. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to RPGLIFE.NS's ROE of +0.21%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to RPGLIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check RPGLIFE.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, AARTIDRUGS.BO has a market cap of 34.4B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while AARTIDRUGS.BO trades at ₹365.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas AARTIDRUGS.BO's P/E ratio is 17.67. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to AARTIDRUGS.BO's ROE of +0.14%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to AARTIDRUGS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check AARTIDRUGS.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, AARTIDRUGS.NS has a market cap of 34.4B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while AARTIDRUGS.NS trades at ₹366.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas AARTIDRUGS.NS's P/E ratio is 17.66. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to AARTIDRUGS.NS's ROE of +0.14%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to AARTIDRUGS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check AARTIDRUGS.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, NOVARTIND.NS has a market cap of 34.3B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while NOVARTIND.NS trades at ₹1,351.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas NOVARTIND.NS's P/E ratio is 36.89. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to NOVARTIND.NS's ROE of +0.12%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to NOVARTIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check NOVARTIND.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, NOVARTIND.BO has a market cap of 34.3B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while NOVARTIND.BO trades at ₹1,354.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas NOVARTIND.BO's P/E ratio is 36.74. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to NOVARTIND.BO's ROE of +0.12%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to NOVARTIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check NOVARTIND.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, SOLARA.BO has a market cap of 25.8B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while SOLARA.BO trades at ₹525.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas SOLARA.BO's P/E ratio is -321.17. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to SOLARA.BO's ROE of -0.01%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to SOLARA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check SOLARA.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, SOLARA.NS has a market cap of 25.8B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while SOLARA.NS trades at ₹524.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas SOLARA.NS's P/E ratio is -320.27. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to SOLARA.NS's ROE of -0.01%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to SOLARA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check SOLARA.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, UNICHEMLAB.NS has a market cap of 25.6B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while UNICHEMLAB.NS trades at ₹356.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas UNICHEMLAB.NS's P/E ratio is 10.13. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to UNICHEMLAB.NS's ROE of +0.10%. Regarding short-term risk, MOREPENLAB.BO is more volatile compared to UNICHEMLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check UNICHEMLAB.NS's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, UNICHEMLAB.BO has a market cap of 25.5B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while UNICHEMLAB.BO trades at ₹357.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas UNICHEMLAB.BO's P/E ratio is 10.12. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to UNICHEMLAB.BO's ROE of +0.10%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to UNICHEMLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check UNICHEMLAB.BO's competition here

MOREPENLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MOREPENLAB.BO stands at 24B. In comparison, MOREPENLAB.NS has a market cap of 24B. Regarding current trading prices, MOREPENLAB.BO is priced at ₹42.81, while MOREPENLAB.NS trades at ₹42.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MOREPENLAB.BO currently has a P/E ratio of 24.46, whereas MOREPENLAB.NS's P/E ratio is 25.29. In terms of profitability, MOREPENLAB.BO's ROE is +0.08%, compared to MOREPENLAB.NS's ROE of +0.08%. Regarding short-term risk, MOREPENLAB.BO is less volatile compared to MOREPENLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MOREPENLAB.BO.Check MOREPENLAB.NS's competition here